Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation
Wood, William A.; Deal, Allison M.; Abernethy, Amy; Basch, Ethan; Battaglini, Claudio; Kim, Yoon Hie; Whitley, Julia; Shatten, Charlotte; Serody, Jon; Shea, Thomas; Reeve, Bryce B.
Patient-reported outcomes (PROs), including symptoms and health-related quality of life (HRQOL), provide a patient-centered description of hematopoietic cell transplantation (HCT)-related toxicity. These data characterize the patient experience after HCT and may have prognostic usefulness for long-term outcomes after HCT. We conducted a study of 32 patients after HCT (10 autologous HCT recipients, 11 full-intensity conditioning allogeneic HCT recipients, and 11 reduced-intensity conditioning allogeneic HCT recipients) to determine the feasibility of weekly electronic PRO collection from HCT until day (D) +100. We used questions from the PRO version of the Common Terminology Criteria for Adverse Events to capture symptoms, and the Patient-Reported Outcomes Measurement Information System Global Health scale to measure physical and mental HRQOL. The vast majority (94%) of patients used the electronic PRO system, with only 6% opting for paper-and-pencil only. The median weekly percentage of participants who completed the surveys was 100% in all cohorts through hospital discharge, and remained 100% for the autologous HCT and reduced-intensity allogeneic HCT cohorts through D+100. Patients were satisfied with the electronic system, giving high marks for readability, comfort, and questionnaire length. Symptom severity varied by absolute level and type of symptom across the 3 cohorts, with the full-intensity allogeneic HCT cohort exhibiting the greatest median overall symptom severity, peaking at D+7. Median physical health HRQOL scores decreased with time in the 3 cohorts, and HRQOL was generally correlated with overall symptom severity. Our results demonstrate the feasibility of frequent electronic PROs in the early post-HCT period. Future studies in larger populations to explore predictive models using frequent PRO data for outcomes, including long-term HRQOL and survival, are warranted.
Wood, William A., & Deal, Allison M., & Abernethy, Amy, & Basch, Ethan, & Battaglini, Claudio, & Kim, Yoon Hie, & Whitley, Julia, & Shatten, Charlotte, & Serody, Jon, & Shea, Thomas, & Reeve, Bryce B.. (November 2012). Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, (19:3), p.450 - 459. Retrieved from http://hdl.handle.net/10342/7684
Wood, William A., and Deal, Allison M., and Abernethy, Amy, and Basch, Ethan, and Battaglini, Claudio, and Kim, Yoon Hie, and Whitley, Julia, and Shatten, Charlotte, and Serody, Jon, and Shea, Thomas, and Reeve, Bryce B.. "Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation". Biology of Blood and Marrow Transplantation. 19:3. (450 - 459.), November 2012. September 29, 2020. http://hdl.handle.net/10342/7684.
Wood, William A. and Deal, Allison M. and Abernethy, Amy and Basch, Ethan and Battaglini, Claudio and Kim, Yoon Hie and Whitley, Julia and Shatten, Charlotte and Serody, Jon and Shea, Thomas and Reeve, Bryce B., "Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation," Biology of Blood and Marrow Transplantation 19, no. 3 (November 2012), http://hdl.handle.net/10342/7684 (accessed September 29, 2020).
Wood, William A., Deal, Allison M., Abernethy, Amy, Basch, Ethan, Battaglini, Claudio, Kim, Yoon Hie, Whitley, Julia, Shatten, Charlotte, Serody, Jon, Shea, Thomas, Reeve, Bryce B.. Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. November 2012; 19(3) 450 - 459. http://hdl.handle.net/10342/7684. Accessed September 29, 2020.